Join the Parkinson's Disease group to help and get support from people like you.
Parkinson's Disease News (Page 3)
Related terms: Parkinson's
Costs for MS, Parkinson's and Alzheimer's Meds Keep Rising
THURSDAY, Oct. 31, 2024 – A person battling multiple sclerosis spent an average of $750 in out-of-pocket fees on medicines in 2012, but by 2021 that same patient spent $2,378 annually, a new report...
Antibiotics Reveal Links Between Gut Microbes, Parkinson's
FRIDAY, Oct. 24, 2024 – Certain gut microbes might be linked to a person’s risk of developing Parkinson’s disease, a new study suggests. People prescribed multiple courses of penicillin antibiotics h...
FDA Approves Vyalev for Advanced Parkinson Disease
TUESDAY, Oct. 22, 2024 – The U.S. Food and Drug Administration has approved Vyalev (foscarbidopa and foslevodopa) for adults living with advanced Parkinson disease (PD). Vyalev is the first and only...
FDA Approves Vyalev (foscarbidopa and foslevodopa) for Adults Living with Advanced Parkinson's Disease
NORTH CHICAGO, Ill., Oct. 17, 2024 /PRNewswire/ – AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved Vyalev (foscarbidopa and foslevodopa) as the first...
Injected 'Nanodiscs' Could Bring Brain Stimulation Therapy Without Implants
FRIDAY, Oct. 11, 2024 – Microscopic magnetic nanodiscs could provide a much less invasive means of providing deep brain stimulation, a new study says. The tiny discs – about 250 nanometers across, o...
NFL Hall of Famer Brett Favre Has Parkinson's Disease
TUESDAY, Sept. 24, 2024 – Green Bay Packers legend and NFL Hall of Famer Brett Favre announced Tuesday that he has been diagnosed with Parkinson's disease. Favre, 54, made the announcement while...
Air Pollution Exposure Increases Risk for Parkinson Disease
FRIDAY, Sept. 20, 2024 – Higher exposure to air pollution increases the risk for Parkinson disease (PD), according to a study published online Sept. 16 in JAMA Network Open. Brittany Krzyzanowski,...
SGLT2i Use Linked to Lower Risk for Neurodegenerative Disease in T2DM
WEDNESDAY, Sept. 18, 2024 – For patients with type 2 diabetes, sodium-glucose cotransporter 2 inhibitor (SGLT2i) use is associated with reduced risks for incident dementia and Parkinson disease...
'Exercise Is Medicine' for People With Parkinson's
THURSDAY, Sept 19, 2024 – Exercise, whether moderate- or high-intensity, can help ease Parkinson's symptoms, including fatigue, new research shows. As study lead author Dr. Philip Millar explained,...
Some Diabetes Meds Could Lower Odds for Dementia, Parkinson's
THURSDAY, Sept. 19, 2024 – A specific class of diabetes drug appears to lower people’s risk for dementia and Parkinson’s disease, a new study shows. Sodium-glucose cotransporter-2 (SGLT2) inh...
Genetics Suggest Link Between ALS, Parkinson's Disease
MONDAY, Sept. 16, 2024 – People with rare genetic variants linked to degenerative brain disorders like Parkinson’s disease are at increased risk of developing ALS, a new study finds. Further, having ...
FDA Approves Crexont (carbidopa and levodopa) Extended-Release Capsules for the Treatment of Parkinson’s Disease
BRIDGEWATER, N.J.--(BUSINESS WIRE) August 7, 2024 – Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has appro...
Adamas Announces FDA Approval for Second Indication for Gocovri as an Adjunctive Treatment to levodopa/carbidopa in Parkinson’s Disease Patients Experiencing OFF Episodes
EMERYVILLE, Calif.--(BUSINESS WIRE)--Feb. 1, 2021-- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people...
FDA Approves Kynmobi (apomorphine hydrochloride) Sublingual Film for the Treatment of Parkinson’s Disease OFF Episodes
MARLBOROUGH, Mass.--(BUSINESS WIRE) May 21, 2020 --Sunovion Pharmaceuticals Inc. (Sunovion) announced today that the U.S. Food and Drug Administration (FDA) has approved Kynmobi (apomorphine HCI)...
FDA Approves Ongentys (opicapone) as an Add-On Treatment for Patients with Parkinson’s Disease Experiencing “Off” Episodes
SAN DIEGO – April 27, 2020 – Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily oral Ongentys (opicapone) 25 mg and 50...